KPV vs BPC-157
Research Comparison

Research Overview

KPV and BPC-157 are compared because both have been studied in intestinal inflammation models, and the catalog carries each one alone and both in one capsule product. The KPV research peptide is the tripeptide Lys-Pro-Val, the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). The BPC-157 research peptide is a synthetic 15-residue partial sequence of a protein isolated from human gastric juice (Chang et al., 2011).

Their reported mechanisms differ too: anti-inflammatory signaling in epithelial and immune cells and uptake by the transporter PepT1 for KPV; nitric oxide (NO) and angiogenesis findings, mostly in rats, for BPC-157. Nearly all of the evidence is cell or animal work, and a PubMed search on 9 October 2026 found no study that compared or combined the two.

Structure and Class

KPV is residues 11 to 13 of alpha-MSH, a 13-residue peptide cut from proopiomelanocortin. Its product page lists C16H30N4O4 and 342.43 g/mol, matching PubChem CID 125672. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its product page lists C62H98N16O22, 1419.55 g/mol; PubChem CID 9941957 gives 1419.5 g/mol. BPC stands for body protection compound, the name given to the parent gastric protein.

BPC-157 is about four times heavier. Using the free-peptide masses, one milligram holds about 2.9 µmol of KPV but only 0.70 µmol of BPC-157. Equal masses give roughly four KPV molecules for every BPC-157 molecule.

The catalog also lists Gut Repair (BPC-157 Arginate Salt & KPV): 60 capsules, each with 500MCG BPC-157 arginate salt form and 500MCG KPV, as listed on its product page. For molar work, take the peptide content from the lot certificate, since the arginate counterion adds mass; the same PubMed search found no study of an arginate salt form.

Side by Side

Research Context: KPV

In RAW 264.7 mouse macrophages stimulated with lipopolysaccharide and interferon-gamma, KPV inhibited NO production and NF-kappaB nuclear translocation, the latter maximally between 1 nM and 1 µM. Unlike alpha-MSH, it did not compete for melanocortin-1 receptor binding even at 1 mM and did not raise cyclic AMP (Mandrika et al., 2001). Model: a mouse macrophage cell line.

The intestinal work pairs cell lines with mice. In human intestinal epithelial lines (Caco2-BBE and HT29-Cl.19A) and Jurkat T cells stimulated with pro-inflammatory cytokines, nanomolar KPV inhibited NF-kappaB and MAP kinase signaling and lowered cytokine secretion. Uptake ran through PepT1, a di- and tripeptide transporter induced in inflamed colon. In mice, KPV in drinking water reduced DSS- and TNBS-induced colitis (Dalmasso et al., 2008).

An independent group in Münster reported fewer inflammatory infiltrates and lower colonic myeloperoxidase activity in DSS colitis, and less inflammation in T cell transfer colitis, in mice. KPV also acted in mice with a nonfunctional melanocortin-1 receptor (Kannengiesser et al., 2008). In a colitis-associated tumor model induced with azoxymethane and DSS, KPV lowered tumor formation in wild-type but not PepT1-knockout mice (Viennois et al., 2016).

All of it is cell and rodent work; PubMed lists no clinical trial of KPV. The 2008 uptake study and the 2016 tumor study share a senior investigator, so the Münster study is the main outside check.

Research Context: BPC-157

In an early rat study of ethanol gastric lesions, the NO synthesis inhibitor L-NAME abolished the effect of L-arginine but only weakened that of BPC-157. In rat gastric mucosa homogenates, BPC-157 at 100 µM generated NO at a level comparable to L-arginine, and L-NAME did not block it even at a tenfold higher concentration (Sikiric et al., 1997). Models: rats and rat tissue.

An independent group in Taiwan reported angiogenesis findings: higher vessel density in the chick chorioallantoic membrane assay and in endothelial tube formation, faster blood flow recovery and more vessels in rat hind limb ischemia, and raised VEGFR2 expression and internalization with VEGFR2-Akt-eNOS activation in human vascular endothelial cells (Hsieh et al., 2017). Models: chick embryo, rat and human cell culture.

The nearest gut match to the KPV colitis work is a rat model. A cysteamine enema produced severe colon lesions with transmural inflammation; BPC-157 given by several routes inhibited them at time points from 30 minutes to 72 hours, and comparators, including sulphasalazine and methylprednisolone, also attenuated them (Sikiric et al., 2001). Model: rats, with no cell culture arm.

A PubMed search on 9 October 2026 for BPC-157 or its code PL 14736 returned 228 records, and 174 list P. Sikiric, of the Zagreb group that described the peptide, as an author. An outside review noted that only a handful of groups had studied it in depth, mostly in small rodent models (Gwyer et al., 2019).

The discovering group reports phase II clinical testing in inflammatory bowel disease under the code PL 14736 (Sikiric et al., 2012), and a 2025 review counted only three human pilot studies and found rigorous, large-scale trials lacking (McGuire et al., 2025).

Choosing Between Them for a Research Question

Pick by mechanism first. PepT1-dependent uptake, NF-kappaB or MAP kinase signaling in epithelial or immune cells, and anti-inflammatory activity that does not run through melanocortin receptors have direct precedent with KPV, including human cell-line designs. The NO system, VEGFR2 signaling and angiogenesis have direct precedent with BPC-157, mostly in rats.

Then check the model. The two literatures do not share one. The KPV precedent is chemically induced and T cell transfer colitis in mice; the BPC-157 precedent is cysteamine colon lesions in rats. A direct comparison therefore needs both peptides in one species and model, matched by moles rather than milligrams. A combined arm, mixed or encapsulated, needs single-peptide arms beside it before any effect can be assigned; no published study has run that design.

The two also share a vial with GHK-Cu and TB-500 in the KLOW blend, covered in the GLOW vs KLOW comparison.

Handling and Storage

Both lyophilized products list -20°C for the powder as shipped and 2 to 8°C after reconstitution, protected from light, with freeze/thaw cycles avoided. Let the sealed vial reach room temperature before opening, add diluent slowly down the vial wall, and swirl rather than shake. Neither sequence contains cysteine or methionine, so there is no disulfide to protect and no thioether to oxidize.

For KPV, one degradation route is documented. Under acid, alkali and hydrogen peroxide stress it formed lys-pro-diketopiperazine as the major degradation product, which a validated reversed-phase HPLC method separates from the intact peptide (Pawar et al., 2015). That argues for near-neutral, oxidizer-free solutions. Split stock into single-use aliquots, record the lot number, and base molar calculations on the measured content in the lot certificate from the COA portal. The Gut Repair product page lists sealed capsules at 15 to 25°C in the original container, away from moisture and direct light.

Questions Researchers Ask

KPV vs BPC-157: what is the difference?

Structure, origin and reported mechanism. KPV is a 342.43 g/mol alpha-MSH tripeptide studied for NF-kappaB signaling and PepT1 uptake in cells and mice. BPC-157 is a 1419.55 g/mol gastric protein fragment studied for NO-system and angiogenesis findings, mostly in rats. The KPV research guide and the BPC-157 research guide cover each in depth.

KPV or BPC-157: which has more intestinal research?

BPC-157 has the larger literature, mostly rodent work from one group. KPV has less, but its intestinal work pairs human cell lines with mouse colitis models and includes an independent replication (Kannengiesser et al., 2008). Human data are minimal for both.

BPC-157 vs KPV: has anyone tested them together?

Not in a published study, as of a PubMed search on 9 October 2026. Statements about the pair rest on single-peptide studies in different species and models.

Are KPV and BPC-157 restricted?

The WADA Prohibited List for 2026 names BPC-157 in class S0, non-approved substances, prohibited at all times. KPV is not named, though WADA notes the S0 class is not limited to the substances it names. An FDA page on bulk drug substances that may present significant safety risks lists both among former category 2 substances whose nominations the nominators withdrew; for KPV, FDA states it has not identified any human exposure data on drug products containing it.